Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides.
Synergistic inhibition of HIV replication in cell culture has been reported for many combinations of reverse transcriptase inhibitors. However, the biochemical basis underlying this interaction is in most cases unknown. It has been previously shown that combinations of L-697,661 or U-90152s with AZT or ddC synergistically inhibit HIV-1 replication in cell culture. The combination of AZT with ddC is also favorable with respect to the inhibition of viral replication. However, the corresponding combinations showed no synergy in inhibiting enzyme activity when tested on conventional polymerase assays using homo- or heteropolymeric RNA and DNA as template. Data obtained suggest that amplification of the effect of chain terminators, a consequence of the high potential number of termination sites present on the template, override the synergistic effect expected for the combination of two independent nucleotide analogs. When a saturating amount of enzyme over template:primer was used, and a single site on the template was available for each chain terminator, the combination of AZTTP and ddCTP synergistically inhibited enzyme activity, whereas, as expected, the combination of AZTTP and ddTTP behaved as merely additive. Under similar conditions the combination of U-90152s and AZTTP was also synergistic. These results suggest that synergy found in antiviral assays with combinations having nucleosidic inhibitors is not related to the synergistic inhibition of reverse transcriptase and might be due to the presence in the viral population of virus strains with different sensitivity to the inhibitors.
Villahermosa
M L
ML
Department of Biochemistry and Molecular Biology, University of Navarra, 31080 Pamplona, Spain.
Martinez-Irujo
J J
JJ
Cabodevilla
F
F
Santiago
E
E
D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology*; D001665:Binding Sites; D017931:DNA Primers; D004261:DNA Replication / Q000187:drug effects*; D004279:DNA, Viral / Q000096:biosynthesis / Q000187:drug effects; D054306:Dideoxynucleotides; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D013698:Templates, Genetic; D013942:Thymine Nucleotides / Q000378:metabolism / Q000494:pharmacology; D015215:Zidovudine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology
D019380:Anti-HIV Agents; D017931:DNA Primers; D004279:DNA, Viral; D054306:Dideoxynucleotides; D009838:Oligodeoxyribonucleotides; D013942:Thymine Nucleotides; D015215:Zidovudine; C052873:zidovudine triphosphate; D054303:HIV Reverse Transcriptase; C017216:2',3'-dideoxythymidine triphosphate